Psychological and pharmacological interventions for binge-eating disorder have previously demonstrated efficacy (compared with placebo or waitlist control); thus, we aimed to expand that literature with a review of comparative effectiveness. We searched MEDLINE,(R) EMBASE,(R) Cochrane Library, Academic OneFile, CINAHL (R) for binge-eating disorder treatment articles and selected studies using predetermined inclusion and exclusion criteria. Data were sufficient for network meta-analysis comparing two pharmacological interventions; psychological interventions were analysed qualitatively. In all, 28 treatment comparisons were included in this review: one pharmacological comparison (second-generation antidepressants versus lisdexamfetamine) and 26 psychological comparisons. Only three statistically significant differences emerged: lisdexamfetamine was better at increasing binge abstinence than second-generation antidepressants; therapist-led cognitive behavioural therapy was better at reducing binge-eating frequency than behavioural weight loss, but behavioural weight loss was better at reducing weight. The majority of other treatment comparisons revealed few significant differences between groups. Thus, patients and clinicians can choose from several effective treatment options. Copyright (C) 2017 John Wiley & Sons, Ltd and Eating Disorders Association.
Comparative effectiveness of treatments for binge-eating disorder
Systematic review and network meta-analysis
Peat, C. M., Berkman, N. D., Lohr, K. N., Brownley, K. A., Bann, C. M., Cullen, K., Quattlebaum, M. J., & Bulik, C. M. (2017). Comparative effectiveness of treatments for binge-eating disorder: Systematic review and network meta-analysis. European Eating Disorders Review, 25(5), 317-328. https://doi.org/10.1002/erv.2517
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Development of a novel shared decision making aid for primary immunodeficiency diseases
Community overdose surveillance